Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Kimi Kondo

Concepts (161)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Radiology
4
2017
175
0.600
Why?
Lymphocele
1
2013
2
0.390
Why?
Surgery, Computer-Assisted
1
2013
86
0.360
Why?
Curriculum
4
2018
1074
0.350
Why?
Faculty
1
2013
151
0.340
Why?
Kidney Neoplasms
4
2016
417
0.260
Why?
Kidney Failure, Chronic
1
2013
582
0.250
Why?
Kidney Transplantation
1
2013
702
0.240
Why?
Clinical Competence
1
2013
1261
0.210
Why?
Portasystemic Shunt, Transjugular Intrahepatic
2
2016
37
0.210
Why?
Attitude of Health Personnel
1
2013
1212
0.210
Why?
Angiomyolipoma
2
2016
21
0.210
Why?
Ultrasonography, Interventional
2
2016
163
0.200
Why?
Diagnostic Imaging
2
2016
340
0.180
Why?
Internship and Residency
1
2013
1269
0.180
Why?
Students, Medical
2
2017
380
0.160
Why?
Education, Medical, Undergraduate
2
2018
206
0.140
Why?
Radiology, Interventional
1
2018
49
0.130
Why?
Schools, Medical
2
2018
157
0.120
Why?
Vena Cava Filters
1
2017
68
0.120
Why?
Pregnancy, Abdominal
1
2016
2
0.120
Why?
Thromboembolism
1
2017
129
0.120
Why?
Radiology Information Systems
1
2016
35
0.120
Why?
Biotechnology
1
2016
45
0.120
Why?
Laboratories
1
2017
109
0.120
Why?
Tuberous Sclerosis
1
2016
56
0.120
Why?
Teaching
1
2018
243
0.110
Why?
Organizational Innovation
1
2016
123
0.110
Why?
Hypertension, Portal
1
2016
66
0.110
Why?
Cavernous Sinus
1
2015
16
0.110
Why?
Venous Insufficiency
1
2015
12
0.110
Why?
Prosthesis Design
1
2017
357
0.110
Why?
Venous Thrombosis
1
2017
195
0.110
Why?
Methotrexate
1
2016
234
0.110
Why?
Pulmonary Embolism
1
2017
245
0.110
Why?
Arteriovenous Fistula
1
2015
36
0.110
Why?
Intracranial Arteriovenous Malformations
1
2015
53
0.110
Why?
Personal Satisfaction
1
2017
218
0.110
Why?
Portal Vein
1
2016
120
0.110
Why?
Radiography, Interventional
1
2016
127
0.110
Why?
Radiology Department, Hospital
1
2014
16
0.100
Why?
Hernia, Abdominal
1
2013
5
0.100
Why?
Ascites
1
2013
47
0.100
Why?
Education, Medical, Graduate
1
2018
566
0.100
Why?
Hernia, Inguinal
1
2013
41
0.100
Why?
Intestinal Obstruction
1
2013
54
0.100
Why?
Embolization, Therapeutic
1
2015
246
0.090
Why?
Chemoembolization, Therapeutic
1
2013
88
0.090
Why?
Cholangiocarcinoma
1
2013
110
0.090
Why?
Translocation, Genetic
1
2012
126
0.080
Why?
Education, Medical
1
2014
273
0.080
Why?
Radiography
1
2013
856
0.080
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2011
128
0.080
Why?
Treatment Outcome
6
2016
11744
0.080
Why?
Receptor Protein-Tyrosine Kinases
1
2012
226
0.080
Why?
Disease Progression
3
2013
2857
0.070
Why?
Neoplasms, Multiple Primary
1
2010
57
0.070
Why?
Delivery of Health Care
1
2016
942
0.070
Why?
Carcinoma, Papillary
1
2009
83
0.070
Why?
Drug Resistance, Neoplasm
2
2012
889
0.070
Why?
Piperazines
1
2011
367
0.070
Why?
Neuroblastoma
1
2010
177
0.070
Why?
Pyrazoles
1
2012
516
0.070
Why?
Pyrimidines
1
2011
530
0.060
Why?
Pyridines
1
2012
606
0.060
Why?
Lung Neoplasms
2
2012
2674
0.060
Why?
Liver Neoplasms
1
2013
774
0.060
Why?
Urinary Bladder Neoplasms
1
2009
257
0.060
Why?
DNA Methylation
1
2011
721
0.060
Why?
Anatomic Landmarks
2
2016
31
0.060
Why?
Protein Kinase Inhibitors
1
2012
982
0.060
Why?
United States
4
2018
16041
0.050
Why?
Surveys and Questionnaires
2
2018
6050
0.050
Why?
Aged
5
2016
26251
0.050
Why?
Carcinoma, Non-Small-Cell Lung
1
2012
1194
0.050
Why?
Humans
15
2018
145625
0.050
Why?
Tomography, X-Ray Computed
4
2016
2766
0.040
Why?
Incidence
2
2016
2910
0.030
Why?
Young Adult
4
2016
14240
0.030
Why?
Male
6
2016
73014
0.030
Why?
Intergenerational Relations
1
2017
20
0.030
Why?
Forecasting
1
2018
386
0.030
Why?
Inventions
1
2016
18
0.030
Why?
Hemoperitoneum
1
2016
10
0.030
Why?
Neoplasm Staging
2
2011
1486
0.030
Why?
Portography
1
2016
7
0.030
Why?
Career Choice
1
2018
235
0.030
Why?
Portal Pressure
1
2016
4
0.030
Why?
History, 20th Century
1
2017
330
0.030
Why?
Device Removal
1
2017
149
0.030
Why?
Pregnancy, Ectopic
1
2016
54
0.030
Why?
Injections, Intramuscular
1
2016
140
0.030
Why?
Models, Organizational
1
2016
145
0.030
Why?
Delayed Diagnosis
1
2016
102
0.030
Why?
Female
8
2016
79080
0.030
Why?
Radiation Exposure
1
2016
62
0.030
Why?
Fluoroscopy
1
2016
177
0.030
Why?
Operative Time
1
2016
192
0.030
Why?
Abdominal Pain
1
2016
148
0.030
Why?
Program Development
1
2017
365
0.030
Why?
Radiation Dosage
1
2016
193
0.030
Why?
Carbon Dioxide
1
2016
228
0.030
Why?
Spleen
1
2016
503
0.030
Why?
Liver Cirrhosis
1
2016
276
0.020
Why?
Time Factors
2
2016
7079
0.020
Why?
Bile Ducts, Intrahepatic
1
2013
62
0.020
Why?
Adult
5
2016
40821
0.020
Why?
Retrospective Studies
3
2016
17291
0.020
Why?
Contrast Media
1
2016
492
0.020
Why?
Program Evaluation
1
2017
945
0.020
Why?
Chi-Square Distribution
1
2013
511
0.020
Why?
Ultrasonography
1
2016
788
0.020
Why?
Bile Duct Neoplasms
1
2013
132
0.020
Why?
Genes, Neoplasm
1
2011
26
0.020
Why?
Laparoscopy
1
2016
474
0.020
Why?
Genotype
1
2016
1866
0.020
Why?
Imatinib Mesylate
1
2011
77
0.020
Why?
Gene Expression Regulation, Leukemic
1
2011
56
0.020
Why?
Data Collection
1
2014
647
0.020
Why?
Adolescent
3
2016
22451
0.020
Why?
DNA Copy Number Variations
1
2012
189
0.020
Why?
ras Proteins
1
2012
148
0.020
Why?
Proto-Oncogene Proteins p21(ras)
1
2012
250
0.020
Why?
Kaplan-Meier Estimate
1
2013
959
0.020
Why?
Reoperation
1
2013
633
0.020
Why?
Middle Aged
4
2016
36359
0.020
Why?
Benzamides
1
2011
226
0.020
Why?
Sensitivity and Specificity
1
2015
1992
0.020
Why?
Oncogene Proteins, Fusion
1
2012
212
0.020
Why?
Protein Structure, Tertiary
1
2012
834
0.020
Why?
Oligonucleotide Array Sequence Analysis
1
2011
751
0.020
Why?
Risk Factors
2
2013
10840
0.020
Why?
Genome, Human
1
2011
425
0.020
Why?
Nephrectomy
1
2010
169
0.020
Why?
Neoplasm Metastasis
1
2011
693
0.020
Why?
Kidney
1
2016
1491
0.020
Why?
Sequence Analysis, DNA
1
2011
771
0.020
Why?
Proto-Oncogene Proteins
1
2012
615
0.020
Why?
ErbB Receptors
1
2012
636
0.020
Why?
Algorithms
1
2016
1843
0.020
Why?
Survival Analysis
1
2011
1372
0.020
Why?
Positron-Emission Tomography
1
2009
342
0.020
Why?
Cisplatin
1
2009
346
0.020
Why?
Multivariate Analysis
1
2011
1531
0.020
Why?
Reproducibility of Results
1
2015
3396
0.020
Why?
Models, Molecular
1
2012
1571
0.020
Why?
Cell Line
1
2012
2809
0.010
Why?
Infant, Newborn
1
2016
6449
0.010
Why?
Colorado
1
2013
4588
0.010
Why?
Cell Line, Tumor
1
2011
3538
0.010
Why?
Pregnancy
1
2016
7217
0.010
Why?
Neoplasm Recurrence, Local
1
2009
1156
0.010
Why?
Aged, 80 and over
1
2015
8351
0.010
Why?
Infant
1
2016
10093
0.010
Why?
Child, Preschool
1
2016
11888
0.010
Why?
Prognosis
1
2010
4331
0.010
Why?
Mutation
1
2012
4082
0.010
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2010
1996
0.010
Why?
Antineoplastic Agents
1
2009
2218
0.010
Why?
Magnetic Resonance Imaging
1
2010
3917
0.010
Why?
Child
1
2016
22638
0.010
Why?
Kondo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)